BMS Forgoes Thalassemia Label Expansion Revenues For Rebozyl

Withdraws Reblozyl sBLA

 
• By Ayisha Sharma
  
BMS Is Doing A U-Turn On Its Expansion Plans For Reblozyl • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip